Trials / Completed
CompletedNCT02541084
Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan
Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) Treatment in Real-life Japanese Settings.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 72 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study aims at investigation of the caregiver burden of Wet Age-related Macular Degeneration (wAMD) patients and at the assessment of how much of caregiver burden could be reduced in transitioning from Pro Re Nata to proactive therapy especially in real-life rural settings where public transportations are not readily available.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Anti-VEGF therapy following the Summary of Product Characteristics |
Timeline
- Start date
- 2015-08-18
- Primary completion
- 2016-03-30
- Completion
- 2016-07-30
- First posted
- 2015-09-04
- Last updated
- 2017-08-22
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02541084. Inclusion in this directory is not an endorsement.